Can the targeted drug Cabozantinib treat lung cancer?

Cabozantinib (Cabozantinib) is currently not approved as a standard treatment for first-line lung cancer. However, it may be used to treat lung cancer in some cases, especially for certain subtypes of non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC) or for patients with advanced stages.

NSCLC is the main type of lung cancer, which can be further divided into multiple subtypes, some of which may carry specific genetic variants associated with cabozantinib. Cabozantinib may be an appropriate treatment option for some patients with NSCLC.

Clinical trials and studies have shown that cabozantinib shows some therapeutic efficacy in some EGFR (epidermal growth factor receptor) mutation-positive NSCLC patients. In addition, cabozantinib may also be an effective treatment option for patients with NSCLC who overexpress or have genetic mutations in MET (hepatocyte growth factor receptor).

However, treatment decisions need to be based on the patient's specific circumstances, pathological examination, and genetic testing results. Doctors will develop the best treatment plan based on the patient's condition, type of pathology, genetic variation and other relevant factors. Therefore, if you or someone you know has lung cancer, you should consult a professional doctor early to get the most appropriate treatment advice.

Cabozantinib is not yet available in China and is not included in medical insurance, so it needs to be purchased through overseas channels. There are original drugs abroad, which cost around 35,000~46,000 yuan. Foreign generic drugs are mainly Lao generic drugs and Bangladeshi generic drugs, with prices ranging from 1,300 to 2,700 yuan. The price is much cheaper than original drugs and is more suitable for the needs of patients in ordinary families. The ingredients of original drugs and generic drugs are basically the same.